Synaptogenix Inc (SNPX)

[F1ash]

"As a thought experiment, what would happen if this trial were successful and the market cap got less than one quarter of the bounce that BIIB got? Assuming all the warrants were converted, the share price at a $2B market cap would be $142.

On the downside, if the drug fails, NTRP will still have $25M in cash, with which it can pursue its orphan drug indication for Fragile X (beyond the scope of this report).

I want to be clear: the most likely outcome of this trial is failure. If Alzheimer’s were an easy disease to cure, we would have cured it already. But in my opinion, the share price is far too low considering the tremendous value that would be unlocked by a successful Phase II trial."

https://awesomecapital.wordpress.com/2017/02/18/neurotrope-alzheimers-trial-may-propel-share-price/